A Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis (NCT06454188)
A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients With Active Psoriatic Arthritis (UP-SPOUT)
🩺 Plain-English Summary (8th-Grade Level)
A Randomized, Placebo-controlled, Multicenter, Study to Evaluate the Impact of Upadacitinib on Spondyloarthritis Outcomes in Patients with Active Psoriatic Arthritis (UP-SPOUT)
Who can join: Review the eligibility criteria below.
Location: University Hospitals Cleveland Medical Center — Cleveland, Ohio
Age range: 18 Years
🧪 Interventions in This Study
📋 "Do I Qualify?" — 1-Minute Self Screener
Instant ChecklistFull eligibility criteria are available on the official NIH protocol. View the criteria ↗
📍 All Participating Trial Locations (5 Sites)
- University Hospitals Cleveland Medical Center — Cleveland, Ohio
- Oregon Health and Science University — Portland, Oregon
- University of Pennsylvania — Philadelphia, Pennsylvania
- The Ottawa Hospital Research Institute — Ottawa, Ontario
- Groupe de Recherche en Maladies Osseuses (G.R.M.O.) Inc. — Québec, Quebec
📞 Contact the Study Coordinator
Phone: (587) 400-9524
Email: amanda.carapellucci@carearthritis.com
Coordinator details come directly from the registered NIH protocol. Confirm the study is still recruiting before traveling.
💰 Cost, Insurance & Patient Rights
- 100% Free Items: The investigational treatment and protocol-required procedures are supplied at zero cost by the sponsor.
- Routine Patient Care: Under federal law (ACA § 2709) and many state statutes, routine care costs are covered during participation.
- Voluntary Participation: You may withdraw at any time without affecting your standard medical care.
More studies in Psoriatic Arthritis
- A Study to Determine the Efficacy and Safety of Deucravacitinib Compared With Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Are Naïve to Biologic Disease-modifying Anti-rheumatic Drugs — Gilbert, Arizona
- Psoriatic Arthritis D2P Screening — Philadelphia, Pennsylvania
- Long Term Evaluation of Safety and Efficacy of Tildrakizumab in Patients With Psoriatic Arthritis — Dothan, Alabama
- Apremilast Pregnancy Exposure Registry — La Jolla, California
- Psorcast Mobile Study — Seattle, Washington
- A Study Comparing Risankizumab to Placebo in Participants With Active Psoriatic Arthritis (PsA) Who Have a History of Inadequate Response to or Intolerance to at Least One Disease Modifying Anti-Rheumatic Drug (DMARD) Therapy — Anniston, Alabama
Explore by condition: All Psoriatic Arthritis clinical trials
💡 How to Participate
- Check the checklist above to see if you may qualify.
- Contact the study coordinator using the phone/email above.
- Ask about the visit schedule, what is covered at no cost, and any travel support.
- Confirm with your own doctor before making a decision.